Rinvoq-30mg (Upadacitinib Tablet) 30mg

Rinvoq-30mg is a Janus kinase (JAK) inhibitor used to manage various inflammatory conditions.

• Rheumatoid arthritis: Reduces inflammation and symptoms in adults with moderate to severe rheumatoid arthritis.
• Psoriatic arthritis: Helps manage joint pain and inflammation associated with psoriatic arthritis.
• Ankylosing spondylitis: Alleviates symptoms of this chronic inflammatory condition affecting the spine.
• Atopic dermatitis: Treats moderate to severe atopic dermatitis (eczema) in adults.
• Ulcerative colitis: Manages moderate to severe ulcerative colitis when other treatments have failed or are not recommended.

• Upadacitinib works by selectively inhibiting Janus kinase 1 (JAK1), which modulates cytokine signaling pathways involved in inflammatory and immune responses. This inhibition helps reduce inflammation and the symptoms associated with various autoimmune and inflammatory conditions.

Rinvoq-30mg may cause several side effects, ranging from common to serious.

Common Side Effects

• Diarrhea: Frequent bowel movements or loose stools.
• Headache: Pain or discomfort in the head or neck.
• Upper respiratory tract infection: Symptoms such as a runny nose, sore throat, or congestion.
• Nausea: Feeling sick to the stomach.
• Vomiting: Forceful expulsion of stomach contents.
• Joint pain: Discomfort or soreness in the joints.

Serious or Rare Side Effects

• Serious infections: Increased risk of infections, including tuberculosis (TB) and shingles (herpes zoster).
• Blood clots: Potential formation of blood clots, which can be life-threatening.
• Liver problems: Elevated liver enzymes or liver damage.
• Allergic reactions: Severe allergic reactions, including rash, itching, or swelling.

Rinvoq-30mg should be used with caution and under the supervision of a healthcare provider.

• Allergies: Avoid if allergic to upadacitinib or any of the ingredients.
• Infections: Do not start treatment if you have an active infection unless advised by your healthcare provider.
• Tuberculosis: Test for TB before starting treatment and monitor closely during therapy.
• Liver problems: Use with caution if you have severe liver problems.
• Pregnancy: Safety in pregnancy is unknown; consult your healthcare provider.
• Breastfeeding: Safety during breastfeeding is unknown; consult your healthcare provider.
• Store below 25°C: Keep in the original container to protect from moisture.

Rinvoq-30mg may interact with other medications, potentially affecting its efficacy or increasing the risk of side effects.

Major Interactions (Avoid)

• Biologics: Avoid concurrent use with other biologics or immunosuppressants.
• Live vaccines: Avoid live vaccines during treatment due to increased infection risk.
• Strong CYP3A4 inhibitors: Avoid concurrent use as it may increase upadacitinib levels.

Moderate Interactions (Monitor Closely)

• Moderate CYP3A4 inhibitors: Monitor closely as it may increase upadacitinib levels.
• Moderate CYP3A4 inducers: Monitor closely as it may decrease upadacitinib levels.
• Anticoagulants: Monitor closely for increased risk of bleeding.